Actively Recruiting

Phase 2
Age: 18Years - 85Years
MALE
NCT05857371

Safety and Potential Effect of Innovative Treatment by Adjuvant Injection of Stromal Vascular Fraction From Autologous Adipose Tissue of URethral Stenosis With Endoscopic Urethrotomy

Led by Assistance Publique Hopitaux De Marseille · Updated on 2026-02-04

20

Participants Needed

1

Research Sites

211 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

SURF is a randomised controlled, parallel group, single blind phase II study designed to assess the safety and potential efficacy of an innovative therapeutic strategy for urethral stenosis based on adjuvant injection of autologous Adipose-Derived Stromal Vascular Fraction of Adipose Tissue (ADSVF) during endoscopic urethrotomy (standard care).

CONDITIONS

Official Title

Safety and Potential Effect of Innovative Treatment by Adjuvant Injection of Stromal Vascular Fraction From Autologous Adipose Tissue of URethral Stenosis With Endoscopic Urethrotomy

Who Can Participate

Age: 18Years - 85Years
MALE

Eligibility Criteria

Eligible

You may qualify if you...

  • Signed informed consent
  • Male aged 18 to 85 years
  • Bulbar urethral stenosis 3 cm or less in length
  • At least one urethral dilatation or urethrotomy for bulbar stenosis in the past 24 months
  • Ability to avoid corticosteroids or immunosuppressive drugs for one month after treatment with physician approval if needed
  • Good general health based on medical history and physical exam
  • Body mass index (BMI) greater than 18 to allow fat tissue harvesting
Not Eligible

You will not qualify if you...

  • Urethral stenosis outside the bulbar region
  • Urethral stenosis longer than 3 cm
  • Urethral stenosis on reconstructed penis (e.g., transgender, post amputation)
  • Previous perineal or pelvic radiotherapy
  • Untreated urinary tract infection or perineal infection
  • Penile cancer within the last 5 years
  • Severe, uncontrolled, or progressive infectious, hepatic, hematological, gastrointestinal (except Crohn's disease), endocrine, pulmonary, cardiac, neurological, psychiatric, or cerebral diseases
  • Congenital or acquired immunodeficiencies
  • Contraindications to anesthesia or surgery
  • Use of corticosteroids or immunosuppressive drugs for more than 3 months
  • Active viral infections including HIV, HTLV I and II, hepatitis B and C, or syphilis
  • Administrative restrictions on participation
  • Signs of obstructive voiding symptoms not caused by the stricture
  • Untreated benign prostatic hyperplasia (BPH) or bladder neck contracture (BNC)
  • Diagnosis of urethra, bladder, or prostate cancer within the last 2 years

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Assistance Publique Hopitaux de Marseille

Marseille, France

Actively Recruiting

Loading map...

Research Team

G

Gilles Karsenty, Pr.

CONTACT

A

Alexandra GIULIANI

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

SINGLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here